Definitive Healthcare Corp. Class A DH 深 滬
已收盤 05-08 16:00:00 美东时间
0.9527
+0.031
+3.33%
華盛通- 最 高1.05
- 今 開1.05
- 成交量 41.24万股
- 最 低 0.8947
- 昨 收 0.922
- 總市值 1.37亿
- 52周最高 4.7003
- 市盈率 靜 --
- 換手率 0.29%
- 52周最低 0.8947
- 委 比 14.29%
- 總股本 1.44亿
- 歷史最高 50.30
- 量 比 1.25
- 振 幅 16.84%
- 歷史最低 0.8947
- 每 手 1
- 風險率 1.07%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅172.14%！Alumis获Oppenheimer上调目标价至55美元；摩根大通首予希捷科技"超配"评级，目标价525美元
今日重点评级关注：Oppenheimer：维持Alumis"跑赢大市"评级，目标价从50美元升至55美元；美银证券：维持Rocket Pharmaceuticals"买入"评级，目标价从8美元升至9美元
03-31 16:30
Barclays Maintains Underweight on Definitive Healthcare, Lowers Price Target to $1
Barclays analyst Saket Kalia maintains Definitive Healthcare (NASDAQ:DH) with a Underweight and lowers the price target from $2.75 to $1.
03-30 22:16
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q1
Health care sector has oversold stocks, RSI momentum indicator can help traders predict short term performance. Latest list of oversold players with RSI below 30: GOSS (26.3), BWAY (19.1), DH (20.2).
03-05 19:16
美股大行评级 | 下调居多！多邻国、Elastic、Flutter、欧特克、Zscaler等遭多家机构下调目标价
今日重点评级关注：巴克莱：维持C4 Therapeutics"超配"评级，目标价从5美元升至7美元；富国银行：维持Agilon Health"超配"评级，目标价从1美元升至1.5美元
03-02 14:08
Stephens & Co. Maintains Equal-Weight on Definitive Healthcare, Lowers Price Target to $2
Stephens & Co. analyst Jeff Garro maintains Definitive Healthcare (NASDAQ:DH) with a Equal-Weight and lowers the price target from $3 to $2.
02-28 00:06
Earnings Scheduled For February 26, 2026
Companies Reporting Before The Bell • Enovis (NYSE:ENOV) is estimated to report...
02-26 19:11
美股大行评级 | 花旗上调苹果目标价升至330美元；GPCR、KYMR、MAMA、TERN、WVE等获多家机构上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从12美元升至13美元；Guggenheim：维持Praxis Precision Medicine"买入"评级，目标价从540美元升至760美元
2025-12-10 10:33
Barclays Maintains Underweight on Definitive Healthcare, Lowers Price Target to $2.75
Barclays analyst Saket Kalia maintains Definitive Healthcare (NASDAQ:DH) with a Underweight and lowers the price target from $3 to $2.75.
2025-12-10 00:33
美股大行评级 | 花旗上调英伟达目标价从210美元升至220美元；DraftKings、DoubleVerify遭多家大行下调目标价
今日重点评级关注：Guggenheim：维持InflaRx"买入"评级，目标价从10美元升至22美元；巴克莱：维持Tandem糖尿病护理"超配"评级，目标价从51美元升至55美元
2025-11-11 10:49
Canaccord Genuity Maintains Hold on Definitive Healthcare, Lowers Price Target to $4
Canaccord Genuity analyst David Hynes maintains Definitive Healthcare (NASDAQ:DH) with a Hold and lowers the price target from $5 to $4.
2025-11-11 04:27
